Form 4: ImmuCell Director David Tomsche Increases Stake in Company
SEC Form 4
Director David Tomsche recently acquired additional shares of ImmuCell Corp, increasing his beneficial ownership.
Summary
- David Tomsche, a director at ImmuCell Corp, has acquired additional shares of the company's common stock.
- The transactions occurred between August 15, 2024, and August 19, 2024.
- Tomsche purchased a total of 2,017 shares on August 15 at a price of $3.567 per share, 4,811 shares on August 16 at $3.7171 per share, and 3,172 shares on August 19 at $3.67 per share.
- Following these transactions, Tomsche's direct ownership amounts to 113,606 shares, which includes 6,987 shares held by immediate family members.
Sentiment
Score: 6
Explanation: The sentiment is neutral to slightly positive. The director's purchase suggests confidence, but it's a relatively small transaction.
Positives
- The director's increased investment could be interpreted as a positive signal about the company's prospects.
Industry Context
This type of insider transaction is common and closely watched by investors as it can provide insights into management's confidence in the company's future performance.
Stakeholder Impact
- Shareholders may view the director's purchase as a positive signal.
Key Dates
| Date | Description |
|---|---|
| 08/15/2024 | David Tomsche acquired 2,017 shares of ImmuCell common stock at $3.567 per share. |
| 08/16/2024 | David Tomsche acquired 4,811 shares of ImmuCell common stock at $3.7171 per share. |
| 08/19/2024 | David Tomsche acquired 3,172 shares of ImmuCell common stock at $3.67 per share. |
| 08/19/2024 | Signature date of the Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.